Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $161.00

Merck & Co., Inc. (NYSE:MRK) had its target price increased by Leerink Partners from $127.00 to $161.00 in a report issued on Wednesday,Benzinga reports. Leerink Partners currently has an outperform rating on the stock.

MRK has been the subject of several other research reports. Jefferies Financial Group lowered shares of Merck & Co., Inc. from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Barclays boosted their target price on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. UBS Group increased their target price on shares of Merck & Co., Inc. from $145.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. Wall Street Zen upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Saturday, August 22nd. Finally, Bank of America lifted their price target on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Seventeen investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and an average target price of $151.32.

Merck & Co., Inc. Stock Down 0.5%

MRK opened at $144.02 on Wednesday. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. The company has a market capitalization of $355.33 billion, a PE ratio of 115.22, a P/E/G ratio of 6.30 and a beta of 0.21. The stock’s fifty day moving average is $136.51 and its 200-day moving average is $124.40. Merck & Co., Inc. has a one year low of $77.58 and a one year high of $156.92.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.13. The business had revenue of $16.61 billion during the quarter, compared to analysts’ expectations of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The company’s quarterly revenue was up 5.1% on a year-over-year basis. During the same quarter last year, the business posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, equities analysts predict that Merck & Co., Inc. will post 2.76 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be issued a $0.85 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.4%. Merck & Co., Inc.’s dividend payout ratio is presently 272.00%.

Insider Activity

In other Merck & Co., Inc. news, EVP Jennifer Zachary sold 80,315 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the completion of the sale, the executive vice president directly owned 45,509 shares in the company, valued at approximately $6,073,631.14. This trade represents a 63.83% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP David R. Maraldo sold 18,706 shares of Merck & Co., Inc. stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total value of $2,407,836.32. Following the transaction, the executive vice president directly owned 18,212 shares in the company, valued at approximately $2,344,248.64. This trade represents a 50.67% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 228,238 shares of company stock valued at $29,977,783 in the last ninety days. Corporate insiders own 0.17% of the company’s stock.

Institutional Trading of Merck & Co., Inc.

Several institutional investors have recently made changes to their positions in MRK. California State Teachers Retirement System lifted its position in Merck & Co., Inc. by 12,537.4% in the 2nd quarter. California State Teachers Retirement System now owns 484,720,247 shares of the company’s stock worth $62,286,552,000 after buying an additional 480,884,635 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Merck & Co., Inc. by 0.5% during the 2nd quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock valued at $29,169,479,000 after acquiring an additional 1,073,507 shares in the last quarter. State Street Corp grew its holdings in shares of Merck & Co., Inc. by 1.6% during the 4th quarter. State Street Corp now owns 120,040,168 shares of the company’s stock valued at $12,737,504,000 after acquiring an additional 1,859,990 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Merck & Co., Inc. by 14.8% in the fourth quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock worth $9,098,196,000 after acquiring an additional 11,156,354 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Merck & Co., Inc. by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 60,047,984 shares of the company’s stock worth $6,307,572,000 after acquiring an additional 249,110 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: HSBC raised its price target for Merck (MRK) from $150 to $172 and maintained a “Buy” rating, implying substantial upside from the recent share price. Benzinga analyst update
• Positive Sentiment: Guggenheim also increased its Merck price target to $170, reinforcing the view that the company’s pipeline, newer medicines and potential cancer-drug combinations can support growth beyond Keytruda. Guggenheim increases Merck price target
• Positive Sentiment: Merck is expanding its development pipeline and commercial portfolio to reduce reliance on Keytruda ahead of its 2028 patent and exclusivity challenges. This provides a longer-term growth narrative, although execution and successful launches remain important. Merck pipeline and new drugs
• Neutral Sentiment: Merck’s stock attracted significant investor attention, but the coverage offers limited new fundamental information. Separately, broader pharmaceutical discussion highlighted manufacturing hurdles for personalized cancer vaccines and risks surrounding confidential industry information. Merck and cancer-vaccine risks
• Negative Sentiment: Investors remain concerned that Merck’s valuation looks demanding relative to its growth rate and to faster-growing peers such as Eli Lilly. Those concerns, combined with the future Keytruda revenue gap, likely contributed to the recent weakness despite higher analyst targets. Merck valuation versus Eli Lilly

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures, and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets worldwide through its Human Health and Animal Health businesses.

Merck’s pharmaceutical portfolio includes oncology, infectious disease, cardiology, immunology, and other therapeutic areas. Its products include Keytruda, an immunotherapy used to treat various cancers; Gardasil, a vaccine that helps protect against human papillomavirus (HPV); and Januvia, a treatment for type 2 diabetes.